{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:17Z","timestamp":1791612437551,"version":"4.3.4"},"reference-count":102,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca"},{"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: With the increasing widespread use of GLP-1 RA and dual GIP\/GLP-1 RAs in the treatment of obesity, their safety profile remains a concern for healthcare professionals (HPs). Objective: This study aimed to characterize and evaluate safety data from the EudraVigilance (EV) database for semaglutide (SEM), liraglutide (LIR), and tirzepatide (TIR). Methods: A hierarchical pharmacovigilance approach was applied, integrating SOC- and PT-level analyses with SmPC-based evaluation and both frequentist (ROR, 95% CI) and Bayesian (IC025) disproportionality methods. Within each molecule, reporter type\u2013stratified analyses were performed, while across all molecules, disproportionality analyses were conducted separately in HP reports and in the full database to identify reporting patterns and potential safety signals, including those not described in the SmPCs. Results: Some ADRs, listed in the SmPC of only one or two of the three GLP1-RAs were also reported in the EV database for the other agents whose SmPCs do not specify these ADRs including optic ischemic neuropathy (TIR: 0.28% and LIR: 0.17%), alopecia (LIR: 0.81%), headache (TIR: 2.51%), intestinal obstruction (TIR: 1.55%), angioedema (LIR: 0.19%), hypersensitivity (SEM: 0.58% and LIR: 0.73%), etc. Pancreatitis, in particular, showed a significant but low-magnitude signal, being more frequently reported by HPs compared with non-HPs across all three GLP1-RAs. Additionally, statistically significant signals (IC025 &gt; 0) were observed in both the HPs and full datasets. For example, for SEM vs. TIR, signals were identified for optic ischemic neuropathy (0.17; 0.13), gallbladder disorder (0.09; 0.11), and dysesthesia (0.42; 0.43), respectively. For TIR vs. SEM, signals were observed for injection site erythema (0.05; 0.11), injection site pruritus (0.01; 0.11), and injection site reaction (0.02; 0.08). Conclusions: These findings suggest potential safety signals beyond current SmPC information, emphasizing the need for continuous pharmacovigilance and cautious interpretation of reporting biases.<\/jats:p>","DOI":"10.3390\/ph19060876","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:08:02Z","timestamp":1780535282000},"page":"876","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions\u2014A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-5004","authenticated-orcid":false,"given":"Ioana Rada","family":"Popa Ilie","sequence":"first","affiliation":[{"name":"Endocrinology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 3-5 Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-4613","authenticated-orcid":false,"given":"Steliana","family":"Ghibu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 6A Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-641X","authenticated-orcid":false,"given":"Anca","family":"Butuca","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-1750","authenticated-orcid":false,"given":"Carmen Maximiliana","family":"Dobrea","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-0430","authenticated-orcid":false,"given":"Adina","family":"Frum","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin","family":"Homorodean","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Medical Clinic No. 1, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3128-2763","authenticated-orcid":false,"given":"Adriana Aurelia","family":"Chis","sequence":"additional","affiliation":[{"name":"Association for Excellence in Pharmaceutical Education and Research, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8729","authenticated-orcid":false,"given":"Claudiu","family":"Morgovan","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-Analysis, and Meta-Regression of 47 Randomized Controlled Trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kushner, R.F., Johansen, O.E., Araujo Torres, K., Phan, T.-M., and Marczewska, A. (2025). Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects. Obesities, 5.","DOI":"10.3390\/obesities5020029"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Butuca, A., Dobrea, C.M., Arseniu, A.M., Frum, A., Chis, A.A., Rus, L.L., Ghibu, S., Juncan, A.M., Muntean, A.C., and Laz\u0103r, A.E. (2024). An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database. Biomedicines, 12.","DOI":"10.20944\/preprints202404.1954.v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1002\/prp2.70080","article-title":"Analysis of Reporting Trends of Serious Adverse Events Associated with Anti-Obesity Drugs","volume":"13","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for Adults with Overweight and Obesity: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/bmjnph-2023-000733","article-title":"Pilot Study to Test the Safety, Tolerability and Feasibility of Dulaglutide during a Low-Energy Diet for Weight Loss and Improved Glycaemic Control","volume":"6","author":"Shand","year":"2023","journal-title":"BMJ Nutr. Prev. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study","volume":"92","author":"Burke","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"e90021","article-title":"Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review","volume":"17","year":"2025","journal-title":"Cureus"},{"key":"ref_9","first-page":"991","article-title":"Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale","volume":"18","author":"Lixi","year":"2025","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Castellana, E., and Chiappetta, M.R. (2026). Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends. Hosp. Pharm.","DOI":"10.1177\/00185787251403040"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13326-015-0017-1","article-title":"Exploring Adverse Drug Events at the Class Level","volume":"6","author":"Winnenburg","year":"2015","journal-title":"J. Biomed. Semant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.18295\/squmj.2021.21.02.001","article-title":"Pharmacovigilance","volume":"21","author":"Jose","year":"2021","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"ref_13","unstructured":"MarketStat (2026, April 18). Insights Top-Selling Drugs of 2025: Keytruda Still on Top, but Lilly\u2019s Getting Close. Available online: https:\/\/marketstatics.com\/top-selling-drugs-of-2025-keytruda-still-on-top-but-lillys-getting-close\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1111\/dom.16393","article-title":"Real-world Use of Liraglutide for Weight Management According to Label in the United Kingdom: A Cohort Study Using the Clinical Practice Research Datalink Primary Care Databases","volume":"27","author":"Dcruz","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Milani, I., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., and Capoccia, D. (2024). Sex-Differences in Response to Treatment with Liraglutide 3.0 Mg. J. Clin. Med., 13.","DOI":"10.20944\/preprints202405.0568.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s13679-021-00453-x","article-title":"Sex\/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment","volume":"10","author":"Cooper","year":"2021","journal-title":"Curr. Obes. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40618-023-02196-z","article-title":"Obesity: A Gender-View","volume":"47","author":"Muscogiuri","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40519-020-00907-6","article-title":"Misperceptions and Barriers to Obesity Management: Italian Data from the ACTION-IO Study","volume":"26","author":"Sbraccia","year":"2021","journal-title":"Eat. Weight. Disord.-Stud. Anorex. Bulim. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ije\/dyz273","article-title":"Has the Prevalence of Overweight, Obesity and Central Obesity Levelled off in the United States? Trends, Patterns, Disparities, and Future Projections for the Obesity Epidemic","volume":"49","author":"Wang","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100072","DOI":"10.1016\/j.obpill.2023.100072","article-title":"Weight Management Treatment Modalities in Patients with Overweight or Obesity: A Retrospective Cohort Study of Administrative Claims Data","volume":"7","author":"Kan","year":"2023","journal-title":"Obes. Pillars"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/oby.24254","article-title":"Body Weight Reduction in Women Treated with Tirzepatide by Reproductive Stage: A Post Hoc Analysis from the SURMOUNT Program","volume":"33","author":"Tchang","year":"2025","journal-title":"Obesity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women Encounter ADRs More Often than Do Men","volume":"64","author":"Zopf","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported Adverse Drug Reactions in Women and Men: Aggregated Evidence from Globally Collected Individual Case Reports during Half a Century","volume":"17","author":"Watson","year":"2019","journal-title":"eClinicalMedicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101805","DOI":"10.1016\/j.cegh.2024.101805","article-title":"Safety Profile of Tirzepatide: A Real-World Pharmacovigilance Analysis of EudraVigilance Database","volume":"30","author":"Khurana","year":"2024","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/cd22-0029","article-title":"Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers","volume":"41","author":"Kushner","year":"2023","journal-title":"Clin. Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Liu, L., Chen, J., Wang, L., Chen, C., and Chen, L. (2022). Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1043789"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, L. (2024). A Real-World Data Analysis of Tirzepatide in the FDA Adverse Event Reporting System (FAERS) Database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1397029"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7570\/jomes20059","article-title":"Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes","volume":"30","author":"Seo","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","unstructured":"European Medicines Agency (2015). Saxenda (Liraglutide): EPAR\u2013Product Information, European Medicines Agency."},{"key":"ref_39","unstructured":"European Medicines Agency (2022). Wegovy (Semaglutide): EPAR\u2013Product Information, European Medicines Agency."},{"key":"ref_40","unstructured":"European Medicines Agency (2022). Mounjaro (Tirzepatide): EPAR\u2013Product Information, European Medicines Agency."},{"key":"ref_41","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2022). Class 4 Medicines Defect Information: Novo Nordisk Limited, NovoRapid FlexTouch 100 Units\/Ml and Saxenda FlexTouch (Liraglutide 6 Mg\/Ml)\u2013EL (22)A\/33."},{"key":"ref_42","unstructured":"Rowley, K. (2026, April 18). November 2025 Drug Safety: Recalls for Compounded Semaglutide, Generic Synthroid; Safety Updates and Microneedling Warnings. Available online: https:\/\/news.askapatient.com\/p\/november-2025-drug-safety-recalls-warnings-microneedling."},{"key":"ref_43","unstructured":"BioPharma Dive (2026, April 18). Lilly Warns GLP-1 Knockoffs May Be \u2018Dangerous,\u2019 Escalating War with Compounders. Available online: https:\/\/www.biopharmadive.com\/news\/lilly-obesity-zepbound-compounder-fda-impurity-\/814536\/."},{"key":"ref_44","unstructured":"ByrdAdatto (2026, April 18). Alert: FDA Confirms End of Tirzepatide Drug Shortage. Available online: https:\/\/byrdadatto.com\/banter\/alert-fda-confirms-end-of-tirzepatide-drug-shortage\/."},{"key":"ref_45","unstructured":"U.S. Food and Drug Administration (2026). FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s."},{"key":"ref_46","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2026). MHRA Safety Roundup: February 2026."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_48","first-page":"e98858","article-title":"Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison","volume":"17","author":"Shil","year":"2025","journal-title":"Cureus"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"bvad114.862","DOI":"10.1210\/jendso\/bvad114.862","article-title":"FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report","volume":"7","author":"Mathew","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"ref_52","first-page":"e98935","article-title":"Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report","volume":"17","author":"Nahar","year":"2025","journal-title":"Cureus"},{"key":"ref_53","first-page":"e78090","article-title":"Acute Functional Gastric Outlet Obstruction Associated with Low-Dose Tirzepatide","volume":"17","author":"Iskander","year":"2025","journal-title":"Cureus"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","first-page":"e38263","article-title":"Liraglutide-Induced Pancreatitis: A Case Report and Literature Review","volume":"15","author":"Javed","year":"2023","journal-title":"Cureus"},{"key":"ref_56","first-page":"e21616","article-title":"Liraglutide Overdose-Induced Acute Pancreatitis","volume":"14","author":"AlSaadoun","year":"2022","journal-title":"Cureus"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Guo, H., Guo, Q., Li, Z., and Wang, Z. (2024). Association between Different GLP-1 Receptor Agonists and Acute Pancreatitis: Case Series and Real-World Pharmacovigilance Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1461398"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00380","DOI":"10.14309\/crj.0000000000000380","article-title":"Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient","volume":"7","author":"Dolan","year":"2020","journal-title":"ACG Case Rep. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF01536153","article-title":"Histochemical and Ultrastructural Characteristics of Tubular Complexes in Human Acute Pancreatitis","volume":"34","author":"Willemer","year":"1989","journal-title":"Dig. Dis. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e70113","DOI":"10.1002\/edm2.70113","article-title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"bqae155","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and Pharmacology of Effects of GLP-1-Based Therapies on Gastric, Biliary and Intestinal Motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020199"},{"key":"ref_64","first-page":"e96771","article-title":"Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy","volume":"17","author":"Wen","year":"2025","journal-title":"Cureus"},{"key":"ref_65","first-page":"e52564","article-title":"Tendency of Semaglutide to Induce Gastroparesis: A Case Report","volume":"16","author":"Chaudhry","year":"2024","journal-title":"Cureus"},{"key":"ref_66","first-page":"e91679","article-title":"Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient","volume":"17","author":"Singhal","year":"2025","journal-title":"Cureus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, Delayed Gastric Emptying, and Intraoperative Pulmonary Aspiration: A Case Report","volume":"70","author":"Klein","year":"2023","journal-title":"Can. J. Anesth.\/J. Can. D\u2019anesth\u00e9sie"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The Effect of Semaglutide 2.4 Mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults with Obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20420188251406456","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 Receptor Agonists and Gallbladder Disease Risk: Insights into Molecular Mechanisms and Clinical Implications","volume":"16","author":"Eslam","year":"2025","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal Safety of Semaglutide and Tirzepatide vs. Placebo in Obese Individuals without Diabetes: A Systematic Review and Meta Analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann. Saudi Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"108087","DOI":"10.1016\/j.diabres.2020.108087","article-title":"Cholelithiasis in Patients Treated with Glucagon-Like Peptide-1 Receptor: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"161","author":"Nreu","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like Peptide-1 Receptor Expression in the Human Eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2526327","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41433-025-03718-0","article-title":"Are Synthetic Incretins Associated with Ischaemic Optic Neuropathy?","volume":"39","author":"Gregory","year":"2025","journal-title":"Eye"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications","volume":"11","author":"Burke","year":"2025","journal-title":"Ski. Appendage Disord."},{"key":"ref_79","first-page":"e94126","article-title":"Allodynia and Dysesthesia Associated with Semaglutide and Tirzepatide","volume":"17","author":"Ahern","year":"2025","journal-title":"Cureus"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-Weekly Semaglutide 7\u00b72 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"luae105","DOI":"10.1210\/jcemcr\/luae105","article-title":"Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide","volume":"2","year":"2024","journal-title":"JCEM Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"luac014.039","DOI":"10.1210\/jcemcr\/luac014.039","article-title":"Injection Site Reaction Induced by Liraglutide Use in a Female Patient with Obesity","volume":"1","author":"Ayhan","year":"2023","journal-title":"JCEM Case Rep."},{"key":"ref_83","first-page":"1023","article-title":"Injection Site Reaction during Liraglutide Therapy","volume":"3","author":"Kamila","year":"2019","journal-title":"J. Dermatol. Plast. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jdv.20512","article-title":"Exploring the Hair Loss Risk in Glucagon-like Peptide-1 Agonists: Emerging Concerns and Clinical Implications","volume":"39","author":"Buontempo","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"pe153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia Associated with the Use of Semaglutide and Tirzepatide: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_86","unstructured":"World Health Organization (2026, May 15). WHO Medical Product Alert\u2013Semaglutide Medicines and NAION. Available online: https:\/\/www.who.int\/news\/item\/27-06-2025-27-06-2025-semaglutide-medicines-naion."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/ijd.70133","article-title":"Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review","volume":"65","author":"Branyiczky","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_88","unstructured":"Medicines and Healthcare Products Regulatory Agency (2026, May 15). MHRA Updates Guidance for GLP-1 Prescribers and Patients, Available online: https:\/\/www.gov.uk\/government\/news\/mhra-updates-guidance-for-glp-1-prescribers-and-patients?utm_source=chatgpt.com."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Popa Ilie, I.R., Dobrea, C.M., Butuca, A., Homorodean, C., Morgovan, C., Vonica-Tincu, A.L., Gligor, F.G., Ghibu, S., and Frum, A. (2024). Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121631"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Noguchi, Y., Yoshizawa, S., Aoyama, K., Kubo, S., Tachi, T., and Teramachi, H. (2021). Verification of the \u201cUpward Variation in the Reporting Odds Ratio Scores\u201d to Detect the Signals of Drug\u2013Drug Interactions. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101531"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Pono, P., Cheng, V., Skerrett, V., and Jones, A.M. (2025). Post-Marketing Pharmacovigilance Study of Darunavir in the United Kingdom: An Analysis of Adverse Drug Reactions Reported to the MHRA. Pharmacoepidemiology, 4.","DOI":"10.3390\/pharma4040025"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Calapai, F., Mannucci, C., McQuain, L., and Salvo, F. (2023). Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase. Pharmaceuticals, 16.","DOI":"10.20944\/preprints202308.1495.v1"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and Interpreting Disproportionality Analyses Derived from Spontaneous Reporting Systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-014-0204-5","article-title":"Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in VigiRank","volume":"37","author":"Caster","year":"2014","journal-title":"Drug Saf."},{"key":"ref_95","unstructured":"World Health Organization\u2013Uppsala Monitoring Centre (WHO-UMC) (2016). Measures of Disproportionate Reporting, WHO-UMC."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Popa Ilie, I.R., Vonica-Tincu, A.L., Dobrea, C.M., Butuca, A., Frum, A., Morgovan, C., Gligor, F.G., and Ghibu, S. (2024). Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102273"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpowsour.2014.05.003","article-title":"Alkaline stable C2-substituted imidazolium-based cross-linked anion exchange membranes for alkaline fuel cell applications","volume":"266","author":"Lin","year":"2014","journal-title":"J. Power Sources"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104410","DOI":"10.1016\/j.reactfunctpolym.2019.104410","article-title":"Zinc heterocyclic vinyl complexes and their gamma-irradiated derivatives: From the metal to antimicrobial materials","volume":"146","author":"Bucio","year":"2020","journal-title":"React. Funct. Polym."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s11224-023-02245-6","article-title":"Complexes of zinc(II) chloride and acetate with propargylimidazoles: Synthesis, structure and non-covalent interactions","volume":"34","author":"Sterkhova","year":"2023","journal-title":"Struct. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S1600576714022985","article-title":"Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination","volume":"48","author":"Krause","year":"2015","journal-title":"J. Appl. Crystallogr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT\u2014Integrated space-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. A"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. C"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/876\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:17:47Z","timestamp":1780535867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":102,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060876"],"URL":"https:\/\/doi.org\/10.3390\/ph19060876","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}